Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

GSK2801, a BAZ2/BRD9 Bromodomain Inhibitor, Synergizes with BET Inhibitors to Induce Apoptosis in Triple-Negative Breast Cancer.

Bevill SM, Olivares-Quintero JF, Sciaky N, Golitz BT, Singh D, Beltran AS, Rashid NU, Stuhlmiller TJ, Hale A, Moorman NJ, Santos CM, Angus SP, Zawistowski JS, Johnson GL.

Mol Cancer Res. 2019 Jul;17(7):1503-1518. doi: 10.1158/1541-7786.MCR-18-1121. Epub 2019 Apr 18.

PMID:
31000582
2.

Application of Integrated Drug Screening/Kinome Analysis to Identify Inhibitors of Gemcitabine-Resistant Pancreatic Cancer Cell Growth.

Krulikas LJ, McDonald IM, Lee B, Okumu DO, East MP, Gilbert TSK, Herring LE, Golitz BT, Wells CI, Axtman AD, Zuercher WJ, Willson TM, Kireev D, Yeh JJ, Johnson GL, Baines AT, Graves LM.

SLAS Discov. 2018 Sep;23(8):850-861. doi: 10.1177/2472555218773045. Epub 2018 May 9.

PMID:
29742358
3.

Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.

Van Swearingen AED, Sambade MJ, Siegel MB, Sud S, McNeill RS, Bevill SM, Chen X, Bash RE, Mounsey L, Golitz BT, Santos C, Deal A, Parker JS, Rashid N, Miller CR, Johnson GL, Anders CK.

Neuro Oncol. 2017 Oct 19;19(11):1481-1493. doi: 10.1093/neuonc/nox052.

4.

Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex.

Zawistowski JS, Bevill SM, Goulet DR, Stuhlmiller TJ, Beltran AS, Olivares-Quintero JF, Singh D, Sciaky N, Parker JS, Rashid NU, Chen X, Duncan JS, Whittle MC, Angus SP, Velarde SH, Golitz BT, He X, Santos C, Darr DB, Gallagher K, Graves LM, Perou CM, Carey LA, Earp HS, Johnson GL.

Cancer Discov. 2017 Mar;7(3):302-321. doi: 10.1158/2159-8290.CD-16-0653. Epub 2017 Jan 20.

5.

The E3 ligase PARC mediates the degradation of cytosolic cytochrome c to promote survival in neurons and cancer cells.

Gama V, Swahari V, Schafer J, Kole AJ, Evans A, Huang Y, Cliffe A, Golitz B, Sciaky N, Pei XH, Xiong Y, Deshmukh M.

Sci Signal. 2014 Jul 15;7(334):ra67. doi: 10.1126/scisignal.2005309.

6.

SWI/SNF chromatin-remodeling factor Smarcd3/Baf60c controls epithelial-mesenchymal transition by inducing Wnt5a signaling.

Jordan NV, Prat A, Abell AN, Zawistowski JS, Sciaky N, Karginova OA, Zhou B, Golitz BT, Perou CM, Johnson GL.

Mol Cell Biol. 2013 Aug;33(15):3011-25. doi: 10.1128/MCB.01443-12. Epub 2013 May 28.

7.

MicroRNA 9-3p targets β1 integrin to sensitize claudin-low breast cancer cells to MEK inhibition.

Zawistowski JS, Nakamura K, Parker JS, Granger DA, Golitz BT, Johnson GL.

Mol Cell Biol. 2013 Jun;33(11):2260-74. doi: 10.1128/MCB.00269-13. Epub 2013 Mar 25.

8.

[Immunologic-enzymatic determination of prostatic acid phosphatase in human serum].

Heil W, Rick W, Golitz B.

Internist (Berl). 1985 Aug;26(8):523-7. German. No abstract available.

PMID:
3902709

Supplemental Content

Loading ...
Support Center